The case for & against
Bull & Bear analysis
Bullish
Aurora Cannabis Inc. (NASDAQ: ACB) is a leading player in the global medical cannabis market, with significant operations across Canada, Europe, Australia, and other international markets. Known for its high-quality production methods and strong regulatory expertise, Aurora has focused on high-margin medical cannabis offerings, distinguishing itself from competitors primarily targeting the consumer cannabis segment. It is well-positioned within the expanding global medical cannabis industry, aiming to leverage emerging markets for sustained growth.
Bull says
- ↑FY26 net revenue $289M (beat forecasts); adjusted EBITDA $54M.
- ↑Adjusted gross margin rose to 64% on value-chain efficiencies.
- ↑International markets account for 55% of revenue; leading in Germany & Poland.
- ↑Ended FY26 with $165M cash and zero debt for expansion.
- ↑Safari acquisition expected to deliver positive EBITDA in FY27.
- ↑Attractive valuation with ~11.6% earnings yield and ~0.4% dividend yield.
Bear says
- ↓Canadian reimbursement changes may slash top-line by ~30%.
- ↓Rising competition in Germany intensifies price pressure on margins.
- ↓High stock volatility deters risk-averse investors.
- ↓Technical indicators weak: bearish moving averages and high short interest.
- ↓Limited scale versus larger peers could hamper market share gains.
- ↓Negative quality metrics raise doubts on operational resilience.